ABSTRACT
INTRODUCTION
Neonatal mortality and morbidity in cases with isolated congenital diaphragmatic hernia (CDH) depend on the severity of pulmonary hypoplasia and pulmonary arterial hypertension (PAH), and fetal tracheal occlusion has been proposed in order to prevent these complications and therefore to increase neonatal survival 1 -3 . However, prenatal prediction of those fetuses that will present with a severe form of CDH at birth is challenging, which makes it difficult to identify with any precision the best candidates for fetal intervention. Furthermore, neonatal mortality rates appear to vary between different centers all over the world, which may be related to differences in the standardization of perinatal management, in hidden mortality, in assessment and in the use of prenatal intervention 4, 5 . Standard classification of fetuses with isolated CDH according to prognosis is necessary in order to determine the best perinatal management and also to enable better comparison between centers.
A European group suggested classifying fetuses with isolated CDH into extremely severe, severe, moderate and mild forms, based on the observed/expected lung-to-head ratio (LHR) and the presence of herniated liver in the fetal thorax 6, 7 . Several fetal parameters have been proposed in order to predict neonatal outcome in isolated CDH based on lung sizes, position of the liver and pulmonary vasculature status 6,8 -20 . However, as yet there is no consensus as to which parameter is most accurate and useful in predicting neonatal outcome in these cases.
In this study, therefore, we evaluated prospectively different ultrasound parameters in 108 fetuses with isolated CDH in order to analyze the accuracy and the probability of each parameter to predict postnatal survival and severe PAH, providing a basis for classifying the cases according to the severity of CDH. Our series underwent neither fetal surgery nor termination of pregnancy.
PATIENTS AND METHODS
Between January 2004 and December 2010, we conducted a prospective observational study in our tertiary Fetal Medicine Unit, evaluating 108 fetuses with isolated CDH (82 left-sided and 26 right-sided). Inclusion criteria were: (1) gestational age established by last menstrual period in accordance with first-/second-trimester ultrasonography; (2) confirmed ultrasound diagnosis of CDH; (3) normal fetal karyotype; (4) absence of other structural anomalies; (5) no fetal surgery. The protocol was approved by the local ethics committee. The pregnant patients were informed that the results of the study would not be used to modify their perinatal management. The perinatologists, ultrasonographers and surgeons in charge were unaware of the results of the lung volume measurements. Termination of pregnancy was not performed since it is not permitted in our country.
Fetal lung parameters
Using a Voluson 730 (GE Healthcare, Zipf, Austria) ultrasound machine we evaluated between 26 and 30 weeks the following fetal lung parameters: (1) side of the diaphragmatic defect (left or right); (2) presence of polyhydramnios (amniotic fluid index > 25 cm); (3) presence of fetal liver herniated into the fetal thorax ('liverup'); (4) LHR; (5) observed/expected LHR (o/e-LHR); (6) observed/expected contralateral fetal lung volume (o/e-ContFLV) ratio; (7) observed/expected total fetal lung volume (o/e-TotFLV) ratio; (8) ultrasonographic fetal lung volume/fetal weight ratio (US-FLW); (9) observed/expected contralateral pulmonary artery diameter (o/e-ContPA) ratio; (10) observed/expected main pulmonary artery diameter (o/e-MPA) ratio; and (11) contralateral vascularization index (Cont-VI). In addition, the following data were evaluated: (12) gestational age at diagnosis; (13) gestational age at birth; and (14) newborn weight.
The LHR was measured using two-dimensional (2D) ultrasonography by multiplying the two longest perpendicular diameters of the contralateral lung at the level of the four-chamber view of the heart and dividing this by the head circumference (measured in mm) 21, 22 . We calculated o/e-LHR by comparing the LHR with the expected value for gestational age on 2D ultrasound 6, 23 . We determined o/e-ContFLV and o/e-TotFLV by estimating the contralateral and total lung volumes, respectively, using Virtual Organ Computer-aided AnaLysis (VOCAL TM ) software (Sonoview software, GE Healthcare), rotating the three-dimensional (3D) image 30
• degrees as described previously 16, 20 , and comparing them to the expected values for gestational age 24, 25 . US-FLW was the ratio between total fetal lung volume as estimated by 3D ultrasound and the estimated fetal weight using the Hadlock equation, which has been demonstrated not to vary throughout gestational age 19 . Fetal lung sizes were represented by LHR, o/e-LHR, o/e-ContFLV, o/e-TotFLV and US-FLW.
The o/e-ContPA and the o/e-MPA were evaluated by measuring the contralateral and the main pulmonary artery diameters on a cross-sectional image of the fetal chest at the level of the three vessels (main pulmonary artery, ascending aorta and superior vena cava) in the short-axis view of the fetal heart 18, 26 , and comparing them to the expected values for gestational age 27 . Cont-VI was calculated using the 3D power Doppler histogram as reported previously 17 and using the same power Doppler presets (angio mode, cent; smooth, 4/5; frequency, low; quality, 16; density, 6; enhance, 16; balance, G> 150; filter, 2; actual power, 2 dB; pulse repetition frequency, 0.9). The 3D volume of the fetal thorax was acquired and the contralateral lung volume was measured in the transverse plane using VOCAL TM software (rotation of 30 • degrees). A 3D power Doppler histogram was used to determine the vascularization index (VI) from inbuilt computer algorithms which calculate the color voxel to total voxel ratio. This percentage of color flow Doppler within the lung is indicative of the vessels that are present as compared with the background non-vascular parenchyma. Since it has been demonstrated previously that fetal pulmonary VI does not vary throughout gestation 17 , an observed-toexpected ratio was unnecessary for this parameter. Fetal pulmonary vasculature was evaluated by the pulmonary artery diameters (o/e-ContPA and o/e-MPA) and Cont-VI.
Perinatal management
All fetuses with prenatal diagnosis of isolated CDH were followed in our Fetal Medicine Unit and were delivered in our Children's Hospital. All babies were treated following the same protocol 28 . Briefly, the neonates were intubated in the delivery room and admitted immediately to the neonatal intensive care unit. Immediate ventilator support was initiated in all cases, with high-frequency oscillatory ventilation when necessary, followed by delayed CDH repair in all cases. The treatment protocol did not include extracorporeal membrane oxygenation (ECMO), either pre-or postoperatively, as this treatment modality is not available at our institution. Inhaled nitric oxide (iNO) was administered in cases of persistent PAH verified by a pre-vs postductal saturation difference of > 10%, confirmed by echocardiography. Hemodynamic support was achieved by volume expansion and administration of dobutamine (10-20 µg/kg/min) and norepinephrine (0.5-2 µg/kg/min) when necessary. Preoperative respiratory and hemodynamic stabilization, required before delayed CDH repair was performed, was defined by the following criteria: (a) normal hemodynamic variables (mean blood pressure > 40 mmHg with urine output > 2 mL/kg/h) without need for inotropic agents; (b) absence of PAH after discontinuation of iNO; (c) successful weaning to conventional mechanical ventilation with moderate values of peak inspiratory pressure (15-20 cmH 2 O) and adequate oxygenation, achieved with FiO 2 ≤ 40%.
Outcomes and statistical analysis
The primary outcome was neonatal survival to 28 days. The secondary outcome was postnatal diagnosis of severe PAH. Severe PAH was considered when the neonate presented with profound cyanosis associated with echocardiographic continuous right-to-left shunting through a persistent ductus arteriosus and a persistent difference in pre-to postductal saturation gradient > 20%, despite the use of iNO 29 . Data were analyzed using Student's t and chi-square tests to evaluate the association of the ultrasound parameters with neonatal survival and with postnatal diagnosis of severe PAH. Correlations between variables were evaluated by Pearson test. Receiver-operating characteristics (ROC) curves were also calculated to evaluate the accuracy of each variable in the prediction of neonatal survival and postnatal diagnosis of severe PAH, by comparing the areas under the curves (AUCs). Best cut-offs (points with the highest sensitivity and lowest rate of false positivity) were then established. The accuracy of each ultrasound parameter to predict both outcomes was calculated using the best cut-off obtained from the ROC curve analysis using the following equation: accuracy = (number of true positives + number of true negatives)/total number of measurements. 30 -32 . The probabilities for the events (neonatal survival and severe PAH) based on each ultrasound parameter were also calculated using regression. Based on the probabilities of neonatal survival and postnatal diagnosis of PAH, a prognostic classification of CDH was established (Statistica, version 9, StatSoft Inc., Tulsa, OK, USA). Multivariable studies were performed using logistic regression and factor analysis (SPSS for Windows version 17). Statistical differences were considered to be significant when P < 0.05.
RESULTS
The neonatal mortality rate in our series was 64.8% (70/108). All survivors were doing well at 6 months. Severe PAH was diagnosed postnatally in 68 (63.0%) cases, and this was statistically associated with neonatal death: 92.6% (63/68) newborns with severe PAH died while 15.0% (7/40) infants without severe PAH died (P < 0.001). Table 1 presents the prenatal characteristics according to neonatal outcome. Liver herniation into the fetal thorax (liver-up), the ultrasonographic parameters representing fetal lung size (LHR, o/e-LHR, o/e-ContFLV, o/e-TotFLV and US-FLW), fetal pulmonary diameters (o/e-ContPA and o/e-MPA) and contralateral lung vascularization (Cont-VI) were statistically associated with either neonatal death or postnatal severe PAH (P < 0.05). Gestational age at diagnosis, polyhydramnios, side of defect, gestational age at birth and birth weight were related to neither neonatal survival nor postnatal diagnosis of severe PAH in this series.
With the exception of o/e-LHR and US-FLW, all fetal ultrasonographic lung parameters correlated statistically with each other (Table S1 ). The ROC curves used to determine the best cut-offs and accuracies for each ultrasound parameter in the prediction of postnatal death and severe PAH are presented in Figure 1 , and the accuracies themselves are given in Tables S2 and  S3 . Considering the parameters representing fetal lung size, those evaluating total lung volumes had greater accuracy than did those evaluating only the contralateral lung, based on the AUCs and the comparison between accuracies (McNemar and Cochran's Q tests, P < 0.01). The o/e-TotFLV had the highest accuracy to predict both neonatal death and severe PAH (83.3% and 86.1%, respectively) when compared with LHR (73.1% and 78.7%, P < 0.01), o/e-LHR (75.9% and 72.2%; P = 0.07) and o/e-ContFLV (75.0% and 78.7%; P = 0.02), but o/e-TotFLV was not superior to US-FLW (80.6% and 75.9%; P = 0.59) and liver-up (79.6% and 74.1%, P = 0.41). However, Cont-VI was the best ultrasound parameter in predicting postnatal death and severe postnatal PAH (88.9% and 91.7%, respectively, P < 0.001), being more accurate than all other ultrasound parameters.
The relative risks (RR) of each parameter for the outcomes are also shown in Tables S2 and S3 . Based on this information, for each ultrasound parameter it was possible to determine the risks for outcomes in isolated CDH. For example, fetuses with o/e-TotFLV < 0. 35 have an approximately four times higher risk of death and postnatal severe PAH than do those with o/e-TotFLV ≥ 0.35 (RR, 5.2 (95% CI, 2.5-11.0) and RR, 3.7 (95% CI, 2.2-6.4), respectively). The probabilities of each parameter to predict neonatal death or survival were calculated, leading to mathematical equations presented in Tables S2  and S3, respectively. A further analysis was performed considering different combinations of parameters, including one parameter Data given as mean ± SD or n (%). ContFLV, contralateral fetal lung volume ratio; ContPA, contralateral pulmonary artery diameter ratio; Cont-VI, vascularization index of the contralateral lung; GA, gestational age; LHR, lung-to-head ratio; Liver-up, > 1/3 of liver herniated into the fetal thorax; MPA, main pulmonary artery diameter ratio; o/e, observed/expected; PAH, pulmonary arterial hypertension; TotFLV, total fetal lung volume; US-FLW, ultrasonographic fetal lung volume/fetal weight ratio. that measures lung size (LHR, o/e-LHR, o/e-ContFLV, o/e-TotFLV or US-FLW) and the presence/absence of liver herniation, and one parameter that measures pulmonary vascularity (Cont-VI or o/e-MPA). ROC curves of the combined variables are shown in Figure 2 and results are presented in Tables S4 and S5 . There was no statistically significant difference between these different combinations for the prediction of neonatal survival or postnatal diagnosis of severe PAH (P > 0.05).
Based on the probability estimations of neonatal survival and postnatal diagnosis of PAH using these ultrasound parameters (Tables S2-S5) , isolated CDH could be classified into four groups: extremely severe, severe, moderate and mild (Table 2 ). In our present series, the vast majority (almost 50%) of cases had severe CDH.
DISCUSSION
Many different methods have been proposed to estimate fetal lung size 6,13,21,22,33 -35 . The method used most widely is LHR, which is an uncomplicated means of measuring the contralateral lung size. However, some authors have suggested that LHR may vary throughout gestation 34, 36, 37 , and so o/e-LHR was proposed, which , o/e-TotFLV+Liver-up+Cont-VI; , US-FLW+Liver-up+Cont-VI; , LHR+Liver-up+o/e-MPA;
, o/e-LHR+Liver-up+o/e-MPA; , o/e-ContFLV+Liver-up+o/e-MPA; , o/e-TotFLV+Liver-up+o/e-MPA;
, US-FLW+Liver-up+o/e-MPA; , Reference line. (LHR, lung-to-head ratio; ContFLV, contralateral fetal lung volume; Cont-VI, vascularization index of the contralateral lung; Liver-up, > 1/3 of liver herniated into the fetal thorax; MPA, main pulmonary artery diameter; o/e, observed/expected; TotFLV, total fetal lung volume; US-FLW, ultrasonographic fetal lung volume/fetal weight). Data given as range unless stated otherwise. *Probabilities estimated from equations in Tables S2-S5 . ContFLV, contralateral fetal lung volume; ContPA, contralateral pulmonary artery diameter; Cont-VI, vascularization index of the contralateral lung; LHR, lung-to-head ratio; MPA, main pulmonary artery diameter; o/e, observed/expected; TotFLV, total fetal lung volume; US-FLW, ultrasonographic fetal lung volume/fetal weight.
is adjusted according to gestational age 6, 38 . These two methods use 2D ultrasound technology. In our present study, the gestational age at ultrasound examination did not vary considerably (from 26 to 30 weeks), so it is possible that LHR did not vary much within this narrow age range. Fetal lung volumes can be measured using magnetic resonance imaging (MRI) or 3D ultrasound 10,13,14,20,35,39 -42 . Since fetal lung volumes vary throughout gestation, they should be adjusted either to expected values according to gestational age or to estimated fetal weight 19, 20 . It has been demonstrated that the lung ipsilateral to the diaphragmatic defect is more hypoplastic than is the contralateral one, which suggests that evaluation of both lungs may better estimate the degree of pulmonary hypoplasia in isolated CDH 14 -16,43 . We found that measuring total lung volumes (o/e-TotFLV and US-FLW) predicted neonatal outcome more accurately than did using the contralateral lung measurements (LHR, o/e-LHR and o/e-ContFLV).
Fetal pulmonary vascularity in isolated CDH can be evaluated by measuring pulmonary artery diameters on 2D ultrasound, studying pulmonary arterial flow using 2D color Doppler or estimating the vascular indices using 3D power Doppler ultrasonography 18, 26, 44, 45 . Our study confirmed that evaluation of fetal pulmonary vasculature is useful in the prediction of severe PAH and therefore of neonatal death. The better prediction of neonatal outcomes in isolated CDH by the VI compared with the pulmonary arterial diameters may be explained by the fact that the VI evaluates the vascularity of an entire organ (pulmonary function) while the PA diameters may be more related to pulmonary vessel and lung size.
In this study, we established mathematical equations to calculate the probabilities of the events (neonatal survival/death and severe PAH) by using ultrasound parameters associated with neonatal outcome. Based on these equations, fetuses with isolated CDH were classified according to the prognosis into four groups: those with extremely severe, severe, moderate and mild CDH. The importance of classifying CDH according to severity is that this can be used to guide perinatal management. Fetuses with mild CDH have more than an 80% chance of survival and less than a 20% chance of presenting with severe postnatal PAH, while those with moderate CDH have an approximately 50% chance for each. In both of these cases, postnatal therapy in a specialized center is recommended, while fetal intervention is not. For severe CDH, with an approximately 15% chance of survival and higher than 60% chance of presenting with PAH, fetal tracheal occlusion has been proposed as a therapeutic option 46, 47 . Our initial study demonstrated a potential benefit for fetal tracheal occlusion in severe CDH by improving the survival rate from 5% in non-treated fetuses to 50% after fetal intervention 46 , and these findings have been recently confirmed in a randomized trial 48 . Another therapeutic option for severe CDH is the use of ECMO. However, the benefits of ECMO in such cases need to be evaluated.
This classification also allows comparison of neonatal mortality rates between different centers by matching for severity of the CDH. For example, in our present series, the mortality rate was extremely high (64.8%) when compared with other centers 6, 49, 50 . However, a large proportion (54.6%) of cases in our series had severe or extremely severe CDH. This can be explained by the fact that in our series there were no terminations of pregnancy or fetal interventions. Furthermore, this series represents cases diagnosed prenatally, many of which were referred to our center due to their severity because we offer fetal therapy for severe CDH (on a referral bias).
In our study, fetuses with right and left CDH were analyzed together since the aim of the present study was to evaluate whether right-sided CDH had worse prognosis than left-sided defect. However, our results demonstrated that right-sided CDH was not associated statistically with poor neonatal outcome, which is not in accordance with other studies 47, 51 . In our opinion, the herniated liver, reduced lung sizes and decreased vascularity are factors related directly to the neonatal outcomes in isolated CDH independent of the side of the defect. Perhaps previous studies did not consider this fact and the right-sided CDH was considered to have poor prognosis, but in reality these cases had liver herniated into fetal thorax, reduced lung sizes and decreased pulmonary vascularity.
In conclusion, neonatal outcome in fetuses with isolated CDH can be predicted by evaluating the lung size, confirming a herniated liver and analyzing the pulmonary vasculature. Measuring the total lung volumes (o/eTotFLV) more accurately predicts neonatal outcome than does measuring only the contralateral lung size (LHR, o/e-LHR and o/e-ContFLV). The prediction of neonatal outcome is more accurate by evaluating the pulmonary vasculature using the VI on 3D power Doppler ultrasound, since it is related more to the postnatal diagnosis of severe PAH, which may be the main cause of death in newborns with isolated CDH. The present study provides mathematical equations to calculate the probabilities of survival/death and severe PAH, which allows classification of affected fetuses according to severity of CDH. This suggested classification may guide the perinatal management of fetuses with isolated CDH and may allow a better comparison between results in different centers.
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